Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

4.21USD
4:00pm EDT
Change (% chg)

$0.11 (+2.68%)
Prev Close
$4.10
Open
$4.08
Day's High
$4.23
Day's Low
$3.95
Volume
219,772
Avg. Vol
323,997
52-wk High
$9.25
52-wk Low
$3.75

BCRX.OQ

Chart for BCRX.OQ

About

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry... (more)

Overall

Beta: 3.47
Market Cap(Mil.): $329.76
Shares Outstanding(Mil.): 80.43
Dividend: --
Yield (%): --

Financials

  BCRX.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -0.62 -- --
ROI: -116.97 2.83 14.89
ROE: -251.64 5.09 16.13

BRIEF-Biocryst Pharmaceuticals Q2 loss per share $0.21

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

Aug 07 2017

BRIEF-Deerfield Management Co reports 6.81 pct passive stake in Biocryst Pharmaceuticals

* Deerfield Management Company, L.p reports a 6.81 percent passive stake in Biocryst Pharmaceuticals Inc as of may 25- sec filing Source text for Eikon: Further company coverage:

Jun 05 2017

BRIEF-Biocryst announces Rapivab pediatric SNDA acceptance

* Says snda has a pdufa goal date for a decision by end of september 2017 Source text for Eikon: Further company coverage:

Jun 05 2017

BRIEF-Robert Ingram named chairman of Biocryst Pharmaceuticals

* Robert Ingram named chairman of Biocryst Pharmaceuticals Inc

May 30 2017

BRIEF-BioCryst reports additional positive results from second interim analysis of APEX-1 trial

* BioCryst reports additional positive results from the second interim analysis of its APEX-1 trial

May 25 2017

BRIEF-Biocryst Pharmaceuticals files for potential shelf offering

* Files for potential shelf offering of up to 11.7 million shares of common stock Source text: (http://bit.ly/2q4i9Bs) Further company coverage:

May 10 2017

BRIEF-Biocryst reports Q1 loss per share of $0.19

* Expects 2017 net operating cash use to be in range of $30 to $50 million

May 04 2017

BRIEF-BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks

* BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks

Apr 12 2017

BRIEF-BioCryst announces Mundipharma receives approval for Mundesine in Japan

* Biocryst announces Mundipharma receives approval for Mundesine in Japan

Apr 03 2017

BRIEF-Biocryst Pharma commences public offering of common stock

* Biocryst Pharmaceuticals commences public offering of common stock

Mar 08 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,291 -3.00
Eisai Co., Ltd (4523.T) ¥5,556 -25.00
Roche Holding Ltd. (ROG.S) CHF240.40 -1.00
Roche Holding Ltd. (RO.S) CHF244.20 -0.30
GlaxoSmithKline plc (GSK.L) 1,479.50 -10.50
Shire PLC (SHP.L) 3,613.00 -151.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates